Treatment of Osteoarthritis With Celecoxib, a Cyclooxygenase-2 Inhibitor: A Randomized Controlled Trial

Efficacy and Tolerability of Celecoxib versus Naproxen in Patients with Osteoarthritis of the Knee: A Randomized, Double-Blind, Double-Dummy Trial

“…Celecoxib versus naproxen in osteoarthritis of the knee change in GI distress (VAS score) was similar in the two treatment groups, but there were fewer discontinuations due to GI adverse events in patients receiving celecoxib than in those receiving naproxen, suggesting celecoxib may have a more favourable GI tolerance profile than naproxen. The results of the present study are consistent with other trials that have demonstrated improved GI tolerance of celecoxib over nonselective NSAIDs, 20,21,25,37 and evidence suggests that celecoxib is associated with fewer tolerancerelated GI adverse events than nonselective NSAIDs. 37 -39 The current study was not designed to evaluate differences between the two drugs in the incidence of serious GI events, such as bleeding or ulcer, but the single serious GI adverse event reported (GI haemorrhage) in a patient receiving naproxen was not deemed to be treatment- Practitioners must balance these current findings with the increased risk of serious GI adverse events known to be associated with NSAIDs.…”

Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition

“…In addition, celecoxib in doses up to 200 mg/kg (Penning et al, 1997) did not produce gastric damage in rats. On the basis of extensive clinical trials, celecoxib was registered by the U.S. (Bensen et al, 1999;Geis et al, 1999b;Lefkowith et al, 2000a,b;Williams et al, 2000b). Celecoxib was as effective as therapeutic doses of conventional NSAIDs and the most effective dose of celecoxib in OA was found to be 200 mg/day in a once daily regimen.…”

“…Celecoxib was as effective as therapeutic doses of conventional NSAIDs and the most effective dose of celecoxib in OA was found to be 200 mg/day in a once daily regimen. A 12-week study in 1093 patients and a 6-week trial in 688 patients demonstrated that celecoxib was as effective as naproxen or diclofenac in relieving signs and symptoms of OA of the knee (Bensen et al, 1999). A total of 1061 patients with OA of the hip were studied for 12 weeks while receiving celecoxib, naproxen, or placebo.…”

Use of NSAIDs, COX‐2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population

“…The COX-2 inhibitors rofecoxib and celecoxib, or coxibs, are part of a new group of agents that have an antiinflammatory effect similar to that of NSAIDs and have been found to be as effective as these drugs in reducing pain and inflammation (11)(12)(13)(14)(15)(16)(17)(18)(19). Clinical trials have demonstrated that coxibs have a low potential for causing upper GI injury compared with NSAIDs (11,15-17,19 -21).…”